Introduction: Repaglinide is a non-sulfonylurea insulin secretory agent, and is one of the "five golden flowers" of oral hypoglycemic drugs. It is characterized by quick action, short action time, and belongs to the ultra-short action, so it is called the dietary blood glucose regulator.It was listed in China in 2000 and has entered the category B of medical insurance.
Indications: mainly for diet control, weight loss and exercise can not effectively control the hyperglycemia of type 2 diabetes (non-insulin-dependent) patients.
Direction and Dosage: Take before meals. Dosage varies from person to person to control blood sugar.When patients self-monitor blood glucose and/or urine glucose, medical staff should monitor blood glucose regularly to determine the minimum effective dose of medication for patients.Usually take this medicine within 15 minutes before meal, the time of taking the medicine can also be controlled within 0-30 minutes before meal.Please refer to the instruction manual for details.
Adverse reactions: immune system disorders, metabolism and nutrition disorders, eye abnormalities, heart diseases, gastrointestinal disorders, liver and gallbladder disorders, skin and subcutaneous tissue abnormalities, etc.
Taboo:
? Patients with known allergy to repaglinide or any of the excipients in repaglinide
? Patients with type 1 diabetes (insulin dependent -IDDM, C-peptide negative diabetes)
? Patients with diabetic ketoacidosis with or without coma
? Severe abnormal liver function
? Accompanied by the use of Gefebezies
Caution: see using story-telling for details.
智藥研習(xí)社官方微信
制藥在線(xiàn)官方微信
2006-2025 上海博華國(guó)際展覽有限公司版權(quán)所有（保留一切權(quán)利）
滬ICP備05034851號(hào)-57
